Active Ingredient History

  • Now
Amitifadine is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) or so-called triple reuptake inhibitor (TRI) which is or was being developed by Euthymics Bioscience It was under development for the treatment of major depressive disorder, but in May 2013, it was reported that the drug failed to show superior efficacy to placebo in a phase IIb/IIIa clinical trial. It was suggested that this may have been due to the drug being underdosed. In September 2017, development of amitifadine for the treatment of major depressive disorder was finally officially discontinued. As of September 2017, it is still listed as being under development for the treatment of alcoholism and smoking withdrawal.   Wikipedia

  • SMILES: Clc1ccc(cc1Cl)[C@]23CNC[C@H]2C3
  • Mol. Mass: 228.12
  • ALogP: 2.85
  • ChEMBL Molecule:
More Chemistry
1-(3,4-dichlorophenyl)-3-azabicyclo-(3.1.0)hexane hydrochloride | amitifadine | dov 216303 | dov 216,303 | dov21947 | dov 21947 | dov 21,947 | dov-21947 | eb-1010


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue